- Home
- CBLL vs GOSS Comparison
CBLL vs GOSS Comparison
Compare CBLL & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBLL
- GOSS
- Stock Information
- Founded
- CBLL 2014
- GOSS 2015
- Country
- CBLL United States
- GOSS United States
- Employees
- CBLL N/A
- GOSS N/A
- Industry
- CBLL
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- CBLL
- GOSS Health Care
- Exchange
- CBLL Nasdaq
- GOSS Nasdaq
- Market Cap
- CBLL 428.8M
- GOSS 501.2M
- IPO Year
- CBLL 2024
- GOSS 2019
- Fundamental
- Price
- CBLL $12.88
- GOSS $3.00
- Analyst Decision
- CBLL Strong Buy
- GOSS Strong Buy
- Analyst Count
- CBLL 5
- GOSS 6
- Target Price
- CBLL $24.20
- GOSS $8.60
- AVG Volume (30 Days)
- CBLL 326.4K
- GOSS 3.1M
- Earning Date
- CBLL 11-04-2025
- GOSS 11-05-2025
- Dividend Yield
- CBLL N/A
- GOSS N/A
- EPS Growth
- CBLL N/A
- GOSS N/A
- EPS
- CBLL N/A
- GOSS N/A
- Revenue
- CBLL $82,813,000.00
- GOSS $44,051,000.00
- Revenue This Year
- CBLL $35.50
- GOSS N/A
- Revenue Next Year
- CBLL $28.24
- GOSS $16.11
- P/E Ratio
- CBLL N/A
- GOSS N/A
- Revenue Growth
- CBLL 37.93
- GOSS N/A
- 52 Week Low
- CBLL $10.01
- GOSS $0.66
- 52 Week High
- CBLL $32.75
- GOSS $3.60
- Technical
- Relative Strength Index (RSI)
- CBLL 56.66
- GOSS 65.28
- Support Level
- CBLL $12.36
- GOSS $2.42
- Resistance Level
- CBLL $13.15
- GOSS $2.71
- Average True Range (ATR)
- CBLL 0.63
- GOSS 0.18
- MACD
- CBLL 0.12
- GOSS 0.07
- Stochastic Oscillator
- CBLL 88.26
- GOSS 92.44
About CBLL CeriBell Inc.
CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.